Planting the seeds of rare disease research

The FDA's Priority Review Voucher Program has planted the seeds for 56 new rare disease treatments, with 42 first-ever therapies blooming where none existed before. 2024 has been the most fruitful year yet -- learn more and join us in asking that this garden is kept flourishing.

Nurturing New Treatments

The FDA's rare pediatric disease priority review voucher program produced an estimated 569 RPD designations from 2012 to 2022. These vouchers are like seeds with the potential to grow rapidly into new treatment options.

New treatments have been developed for 0 indications, including 0 that previously had no FDA-approved options.

The program has awarded 0 vouchers across 0 therapeutic areas. These span 0 distinct treatment modalities.

To learn more, hover over and tap on the flower petals, the sidebar cards, or individual years to explore the ways this programmed nurtured key milestones in rare disease treatment.